Search Medical Condition
Please enter condition
Please choose location from dropdown

Diabetes Prevention Clinical Trials

A listing of Diabetes Prevention medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (50) clinical trials

Prevention of Diabetes in Overweight/Obese Preadolescent Children

Background: The global pandemic obesity has led to increased risk for prediabetes and type 2 diabetes (T2D). Objectives: (i) To evaluate the effect of a 22 weeks multidisciplinary intervention program including exercise on T2D risk in pre-adolescents with high risk to develop T2D, and (ii) To identify the profile of ...

Phase N/A

Type 1 Diabetes Prediction and Prevention (DIPP) Study

Briefly, cord blood samples are collected and HLA-DR-DQ genotypes are determined from newborn babies. Families with a newborn baby carrying a DR-DQ genotype associated with increased risk for T1D are invited to participate in regular follow-up at the age of 3, 6, 9, 12, 18 and 24 months, and thereafter ...

Phase N/A

Prevention of Microvascular Complications in Prediabetes e-PREDICE Study

Background: A significant proportion of pre-diabetics, show macro and micro vascular complications associated with hyperglycaemia. Although many trials have demonstrated the efficacy of lifestyle and pharmaceutical interventions in diabetes prevention, no trial has evaluated the extent to which mid- and long-term complications can be prevented by early interventions on hyperglycaemia. ...

Phase N/A

A Pilot Study of Nocturnal Hypoglycemia Prevention in Type 1 Diabetes Using the Vigilant Diabetes Management Companion

This is a pilot study to determine whether a large-scale randomized trial is feasible. The pilot study will test if the Vigilant Diabetes Management System is effective in adults with T-I Diabetes in preventing nocturnal hypoglycemia, improving moderate hypoglycemia, improving diabetes quality of life and in reducing fear of hypoglycemia. ...

Phase N/A

T1 Diabetes Hypoglycemia Prevention Pilot

This is a single center 12-week Pilot trial with one arm. Subjects will serve as their own controls. The study will include usual care patients on MDI (multiple daily injections) or CSII (continuous subcutaneous insulin infusion) with the additional use of the Vigilant ™ Diabetes Management System. There will be ...

Phase N/A

Prevention of Corticosteroid-induced Glucose Intolerance

Glucose intolerance is frequent and serious complication of corticosteroid therapy. the aim of the study is to examine the hypothesis that co treatment with rosiglitazone can prevent glucose intolerance in patients treated with corticosteroids.

Phase

Soluble Dietary Fibres in the Prevention of Type 2 Diabetes Mellitus

Controlling the glycemic impact of foodstuffs (by reducing the glycemic load of the diet by using soluble dietary fibres) may reduce the glycemic or insulinemic response. This may in turn result in a reduced inhibition of postprandial fat oxidation rate and a lower plasma triacylglycerol concentration A higher postprandial fat ...

Phase N/A

Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance

Subjects with impaired glucose tolerance will be randomized to either rosiglitazone or placebo for a 18 month period. The study will look at baseline, 12 month and 18 month data for exercise tolerance, coronary artery calcification and diabetes indicators.

Phase

PIoglitazone for PrEvention of Restenosis in Diabetic Patients

2.Design This is a randomised, placebo-controlled, double-blinded, multicenter centre study.The patients' clinical data will be recorded on case report forms (CRF). 3.Aim of the study To evaluate the efficacy of Pioglitazone (30 mg/daily) therapy on in-stent late luminal loss in T2DM patients treated with sirolimus-eluting stent for a complex lesion. ...

Phase

Intranasal Insulin for Prevention of Type 1 Diabetes

Children born in Turku, Oulu and Tampere university cities in Finland are screened at birth for the HLA-DQB1 and DQA1 alleles that carry increased risk to or protection from development of type 1 diabetes. Children carrying increased risk are followed at 3-month intervals until 2 years of age and then ...

Phase